Oncological Surgery — MCQs

Q: Which of the following requires the maximum margin of excision?

Dermatofibrosarcoma protuberans. **Explanation:** The correct answer is **Dermatofibrosarcoma Protuberans (DFSP)**. The primary factor determining excision margins is the biological behavior and local invasiveness of the tumor. DFSP is a low-to-intermediate grade cutaneous sarcoma characterized by extensive, subclinical **tentacle-like lateral extensions** (microscopic projections) into the surrounding dermis and subcutaneous fat. Because these extensions often go beyond the clinically visible tumor, standard narrow margins lead to extremely high recurrence rates. Current guidelines recommend a wide local excision with a margin of **2 to 4 cm**, or ideally, Mohs Micrographic Surgery (MMS). **Analysis of Incorrect Options:** * **Malignant Melanoma:** Margins are determined by the **Breslow thickness**. Even for the thickest tumors (>2 mm), the maximum recommended margin is **2 cm**. * **Squamous Cell Carcinoma (SCC):** Standard margins for high-risk SCC are typically **6 mm to 10 mm**. * **Basal Cell Carcinoma (BCC):** This is the least aggressive of the group. Standard excision margins are usually **4 mm to 5 mm** for low-risk lesions. **High-Yield Clinical Pearls for NEET-PG:** * **DFSP Pathognomonic Feature:** Histology shows a characteristic **"storiform" (cartwheel) pattern** of spindle cells and a **"honeycomb" appearance** when invading subcutaneous fat. * **Cytogenetics:** Associated with a translocation **t(17;22)**, leading to overexpression of PDGFB. * **Treatment of Choice:** Mohs Micrographic Surgery (MMS) is preferred over wide local excision to minimize tissue loss while ensuring clear margins. * **Medical Management:** **Imatinib** (a tyrosine kinase inhibitor) is used for metastatic or unresectable DFSP.

Q: The staging system for thymoma was developed by whom?

Masaoka. The correct answer is **A. Masaoka**. ### Explanation The staging of thymic epithelial tumors (thymomas) is primarily based on the **Masaoka Staging System** (later modified as the Masaoka-Koga system). This system is unique because it is based on the degree of **capsular invasion** and the involvement of adjacent structures rather than just tumor size. * **Stage I:** Macroscopically and microscopically completely encapsulated. * **Stage II:** Microscopic transcapsular invasion (IIa) or macroscopic invasion into surrounding fatty tissue (IIb). * **Stage III:** Macroscopic invasion into neighboring organs (pericardium, great vessels, or lungs). * **Stage IV:** Pleural/pericardial dissemination (IVa) or lymphogenous/hematogenous metastasis (IVb). ### Why the other options are incorrect: * **B. Yokohama:** This is not a recognized surgical staging system. It is likely a distractor. * **C. Todani:** This classification is used for **Choledochal cysts** (Types I-V), a high-yield topic in pediatric and hepatobiliary surgery. * **D. Klatskin (often confused with Kluive):** While "Kluive" is a distractor, **Klatskin tumors** refer to hilar cholangiocarcinoma. If the option meant **Bismuth-Corlette**, that is the staging used for those tumors. ### High-Yield Clinical Pearls for NEET-PG: 1. **Most common association:** 30–45% of patients with thymoma have **Myasthenia Gravis**. Conversely, only 10–15% of patients with Myasthenia Gravis have a thymoma. 2. **Treatment of Choice:** Complete surgical resection (**En-bloc Thymectomy**) is the gold standard for resectable tumors. 3. **WHO Classification:** While Masaoka stages the *extent*, the WHO classification (Types A, AB, B1, B2, B3, and C) categorizes thymomas based on *histology* and cytological atypia. 4. **TNM Staging:** Recently, the AJCC/UICC 8th edition introduced a TNM staging system for thymic tumors, but Masaoka-Koga remains the most widely used in clinical practice.

Q: What is the recommended treatment for papillary carcinoma of the thyroid with bony metastasis?

Near total thyroidectomy with radioiodine and radiotherapy. ### Explanation The management of differentiated thyroid cancers (DTC), specifically **Papillary Carcinoma Thyroid (PTC)** with distant metastasis, follows a multimodal approach aimed at both local control and systemic treatment. **Why Option D is Correct:** 1. **Near Total or Total Thyroidectomy:** This is the mandatory first step. Removing all normal thyroid tissue is essential to eliminate the source of thyroglobulin (a tumor marker) and, more importantly, to ensure that subsequent doses of radioactive iodine (RAI) are taken up by the metastatic bone lesions rather than the thyroid gland itself. 2. **Radioiodine (I-131) Therapy:** PTC is typically iodine-avid. RAI is the treatment of choice for distant metastases (lung and bone) after the primary gland is removed. 3. **Radiotherapy (EBRT):** Bone metastases in PTC are often osteolytic and carry a high risk of pathological fractures or spinal cord compression. External Beam Radiation Therapy (EBRT) is added for palliation, pain control, and to stabilize the metastatic site. **Analysis of Incorrect Options:** * **Options A & B:** These are incomplete. Surgery is the cornerstone of management for DTC, even in the presence of metastasis, to facilitate adjuvant therapies. * **Option C:** While it includes surgery and radiotherapy, it misses **Radioiodine**, which is the most specific systemic therapy for thyroid cancer cells. **NEET-PG High-Yield Pearls:** * **Most common site of metastasis in PTC:** Cervical lymph nodes (Level II, III, IV). * **Most common site of distant metastasis:** Lungs (more common than bone). * **Prognostic Scoring:** Use the **AMES** or **MACIS** criteria for PTC. * **Thyroglobulin (Tg):** Used as a postoperative tumor marker to monitor recurrence. * **Treatment of choice for Follicular Carcinoma with bone metastasis:** Also Total Thyroidectomy followed by RAI.

Q: A 3 cm squamous cell carcinoma of the retrornolar trigone is invading the mandible and the medial pterygoid muscle. What is the TNM stage of this tumor?

Stage IV. ### Explanation The TNM staging for Oral Cavity cancers (including the retromolar trigone) is based on the size and depth of invasion (T), nodal involvement (N), and metastasis (M). **1. Why Stage IV is Correct:** According to the AJCC 8th Edition, the T-stage is determined by the extent of local invasion. * **T4a (Moderately Advanced Local Disease):** The tumor invades adjacent structures such as the cortical bone of the mandible or maxilla, deep (extrinsic) muscles of the tongue, maxillary sinus, or skin of the face. * **T4b (Very Advanced Local Disease):** The tumor invades the masticator space (which includes the **medial pterygoid muscle**), pterygoid plates, or skull base, and/or encases the internal carotid artery. In this case, invasion into the **medial pterygoid muscle** automatically classifies the tumor as **T4b**. Any T4 tumor (T4a or T4b) with any N or M status results in a **Stage IV** designation (specifically Stage IVB for T4b). **2. Why Other Options are Incorrect:** * **Stage I:** Requires a T1 tumor (≤2 cm and Depth of Invasion [DOI] ≤5 mm) with no nodal involvement. * **Stage II:** Requires a T2 tumor (>2 cm and ≤4 cm, DOI ≤10 mm) with no nodal involvement. * **Stage III:** Requires a T3 tumor (>4 cm or DOI >10 mm) or a T1/T2/T3 tumor with a single ipsilateral lymph node ≤3 cm (N1). **3. Clinical Pearls for NEET-PG:** * **Retromolar Trigone (RMT):** A unique site where the mucosa is closely attached to the bone; hence, early bone invasion is common. * **Masticator Space:** Involvement of the medial pterygoid often presents clinically as **trismus** (lockjaw), which is a "red flag" for T4b disease. * **Bone Invasion:** Superficial erosion of bone/tooth socket by a gingival primary is not enough to classify as T4; there must be invasion through the cortical bone.

Q: What is the role of neoadjuvant chemotherapy in breast carcinoma patients?

To shrink the tumor to enable breast-conserving therapy. ### Explanation **Neoadjuvant Chemotherapy (NACT)** refers to the administration of systemic chemotherapy before definitive local surgical treatment. **1. Why Option B is Correct:** The primary surgical objective of NACT in breast cancer is **downstaging**. By shrinking a large primary tumor, NACT can convert a patient who was initially a candidate only for a Total Mastectomy into a candidate for **Breast Conserving Surgery (BCS)**. It also helps in downstaging involved axillary lymph nodes, potentially avoiding a morbid axillary lymph node dissection (ALND). **2. Why Other Options are Incorrect:** * **Option A & C:** While NACT treats micrometastases early, it is not a "cure" for established distant metastasis (Stage IV), nor is its primary definition "limiting" metastasis; its role is local downstaging for better surgical outcomes. * **Option D:** Symptomatic relief is the goal of *palliative* chemotherapy. NACT is part of a *curative* intent protocol. **3. NEET-PG High-Yield Pearls:** * **Indications for NACT:** Locally Advanced Breast Cancer (LABC), inflammatory breast cancer, or large tumors where the tumor-to-breast ratio precludes BCS. * **Pathological Complete Response (pCR):** The most important prognostic marker after NACT. It is defined as the absence of invasive cancer in the breast and axilla at the time of surgery. * **Molecular Subtypes:** Triple-negative (TNBC) and HER2-positive breast cancers show the highest rates of pCR with NACT. * **Monitoring:** The clinical response to NACT is monitored via physical exam and imaging (MRI is the most sensitive). If the tumor progresses during NACT, surgery should be performed immediately.

Q: What is the most common site for cancer of the tongue?

Lateral margin of tongue. **Explanation:** The **lateral margin of the tongue** (specifically the middle third) is the most common site for squamous cell carcinoma (SCC) of the tongue, accounting for approximately **75% of cases**. This area is particularly vulnerable due to chronic irritation from jagged teeth or ill-fitting dentures, and the pooling of carcinogens (like alcohol and tobacco) in the floor of the mouth and the adjacent lateral sulcus. **Analysis of Options:** * **A. Base of tongue:** This refers to the posterior one-third (behind the circumvallate papillae). While it is a common site for HPV-associated oropharyngeal cancers, it is less frequent than lateral margin involvement. * **B. Tip of tongue:** This is a rare site for primary malignancy. * **D. Posterior attachment:** This is not a standard anatomical landmark for primary tongue cancer localization; most cancers arise on the mobile (anterior two-thirds) portion. **Clinical Pearls for NEET-PG:** 1. **Histology:** Squamous Cell Carcinoma (SCC) is the most common histological type (>90%). 2. **Lymphatic Spread:** Tongue cancers have a high propensity for early lymphatic spread. The tip drains to Submental nodes (Level I), while the lateral margins drain to Submandibular (Level I) and Deep Cervical nodes (Level II/III). 3. **Premalignant Lesions:** Erythroplakia has a much higher risk of malignant transformation than Leukoplakia. 4. **Prognosis:** Tumors of the posterior third (base) generally have a worse prognosis than the anterior two-thirds because they are often diagnosed late and have a higher rate of bilateral nodal metastasis.

Q: What is the use of injecting methylene blue dye in breast cancer surgery?

Sentinel lymph node biopsy. **Explanation:** **Sentinel Lymph Node Biopsy (SLNB)** is the standard of care for axillary staging in clinically node-negative (cN0) breast cancer. The "Sentinel Node" is defined as the first lymph node(s) to receive lymphatic drainage from the primary tumor. Injecting **Methylene Blue** (or Isosulfan Blue/Patent Blue) into the periareolar area or the peritumoral tissue allows the surgeon to visually track the blue-stained lymphatic channels leading to the blue-stained sentinel node. This allows for targeted removal of only the most relevant nodes, reducing the risk of lymphedema compared to a full axillary dissection. **Analysis of Incorrect Options:** * **A. Tattooing for biopsy:** While dyes or charcoal can be used to mark non-palpable lesions for excision, Methylene Blue is not used for permanent tattooing as it diffuses rapidly. * **B. Marking of tumor cells:** Methylene Blue does not selectively bind to or "stain" breast cancer cells; it follows lymphatic flow. * **D. Photodynamic therapy:** This involves photosensitizers (like porphyrins) and specific light wavelengths to kill cancer cells, not diagnostic blue dyes. **High-Yield Clinical Pearls for NEET-PG:** * **Dual Technique:** The highest identification rate for SLNB is achieved using a combination of **Methylene Blue dye** and **Radioactive Technetium-99m sulfur colloid** (detected via a Gamma probe). * **Contraindication:** SLNB is generally avoided in inflammatory breast cancer. * **Side Effect:** Patients should be warned that Methylene Blue can cause temporary blue-green discoloration of urine and skin. * **Safety Note:** Isosulfan blue carries a small risk of anaphylaxis; Methylene Blue is a safer, cost-effective alternative.

A 40-year-old man presents with pulmonary lesions on chest CT scan. He has a history of melanoma treated with wide local excision and lymph node dissection. Biopsy confirms metastatic melanoma in the pulmonary lesions. His general condition is good, with no evidence of recurrence or extrathoracic disease. What is the most appropriate treatment for this patient?

Q10Easy

What is the use of injecting methylene blue dye in breast cancer surgery?

Oncological Surgery Indian Medical PG Practice Questions and MCQs

Question 1: Which of the following requires the maximum margin of excision?

A. Malignant melanoma
B. Basal cell carcinoma (BCC)
C. Squamous cell carcinoma (SCC)
D. Dermatofibrosarcoma protuberans (Correct Answer)

Explanation: **Explanation:** The correct answer is **Dermatofibrosarcoma Protuberans (DFSP)**. The primary factor determining excision margins is the biological behavior and local invasiveness of the tumor. DFSP is a low-to-intermediate grade cutaneous sarcoma characterized by extensive, subclinical **tentacle-like lateral extensions** (microscopic projections) into the surrounding dermis and subcutaneous fat. Because these extensions often go beyond the clinically visible tumor, standard narrow margins lead to extremely high recurrence rates. Current guidelines recommend a wide local excision with a margin of **2 to 4 cm**, or ideally, Mohs Micrographic Surgery (MMS). **Analysis of Incorrect Options:** * **Malignant Melanoma:** Margins are determined by the **Breslow thickness**. Even for the thickest tumors (>2 mm), the maximum recommended margin is **2 cm**. * **Squamous Cell Carcinoma (SCC):** Standard margins for high-risk SCC are typically **6 mm to 10 mm**. * **Basal Cell Carcinoma (BCC):** This is the least aggressive of the group. Standard excision margins are usually **4 mm to 5 mm** for low-risk lesions. **High-Yield Clinical Pearls for NEET-PG:** * **DFSP Pathognomonic Feature:** Histology shows a characteristic **"storiform" (cartwheel) pattern** of spindle cells and a **"honeycomb" appearance** when invading subcutaneous fat. * **Cytogenetics:** Associated with a translocation **t(17;22)**, leading to overexpression of PDGFB. * **Treatment of Choice:** Mohs Micrographic Surgery (MMS) is preferred over wide local excision to minimize tissue loss while ensuring clear margins. * **Medical Management:** **Imatinib** (a tyrosine kinase inhibitor) is used for metastatic or unresectable DFSP.

Question 2: The staging system for thymoma was developed by whom?

A. Masaoka (Correct Answer)
B. Yokohama
C. Todani
D. Kluive

Explanation: The correct answer is **A. Masaoka**. ### Explanation The staging of thymic epithelial tumors (thymomas) is primarily based on the **Masaoka Staging System** (later modified as the Masaoka-Koga system). This system is unique because it is based on the degree of **capsular invasion** and the involvement of adjacent structures rather than just tumor size. * **Stage I:** Macroscopically and microscopically completely encapsulated. * **Stage II:** Microscopic transcapsular invasion (IIa) or macroscopic invasion into surrounding fatty tissue (IIb). * **Stage III:** Macroscopic invasion into neighboring organs (pericardium, great vessels, or lungs). * **Stage IV:** Pleural/pericardial dissemination (IVa) or lymphogenous/hematogenous metastasis (IVb). ### Why the other options are incorrect: * **B. Yokohama:** This is not a recognized surgical staging system. It is likely a distractor. * **C. Todani:** This classification is used for **Choledochal cysts** (Types I-V), a high-yield topic in pediatric and hepatobiliary surgery. * **D. Klatskin (often confused with Kluive):** While "Kluive" is a distractor, **Klatskin tumors** refer to hilar cholangiocarcinoma. If the option meant **Bismuth-Corlette**, that is the staging used for those tumors. ### High-Yield Clinical Pearls for NEET-PG: 1. **Most common association:** 30–45% of patients with thymoma have **Myasthenia Gravis**. Conversely, only 10–15% of patients with Myasthenia Gravis have a thymoma. 2. **Treatment of Choice:** Complete surgical resection (**En-bloc Thymectomy**) is the gold standard for resectable tumors. 3. **WHO Classification:** While Masaoka stages the *extent*, the WHO classification (Types A, AB, B1, B2, B3, and C) categorizes thymomas based on *histology* and cytological atypia. 4. **TNM Staging:** Recently, the AJCC/UICC 8th edition introduced a TNM staging system for thymic tumors, but Masaoka-Koga remains the most widely used in clinical practice.

Question 3: What is the recommended treatment for papillary carcinoma of the thyroid with bony metastasis?

A. Radiotherapy
B. Radioiodine
C. Near total thyroidectomy with radiotherapy
D. Near total thyroidectomy with radioiodine and radiotherapy (Correct Answer)

Explanation: ### Explanation The management of differentiated thyroid cancers (DTC), specifically **Papillary Carcinoma Thyroid (PTC)** with distant metastasis, follows a multimodal approach aimed at both local control and systemic treatment. **Why Option D is Correct:** 1. **Near Total or Total Thyroidectomy:** This is the mandatory first step. Removing all normal thyroid tissue is essential to eliminate the source of thyroglobulin (a tumor marker) and, more importantly, to ensure that subsequent doses of radioactive iodine (RAI) are taken up by the metastatic bone lesions rather than the thyroid gland itself. 2. **Radioiodine (I-131) Therapy:** PTC is typically iodine-avid. RAI is the treatment of choice for distant metastases (lung and bone) after the primary gland is removed. 3. **Radiotherapy (EBRT):** Bone metastases in PTC are often osteolytic and carry a high risk of pathological fractures or spinal cord compression. External Beam Radiation Therapy (EBRT) is added for palliation, pain control, and to stabilize the metastatic site. **Analysis of Incorrect Options:** * **Options A & B:** These are incomplete. Surgery is the cornerstone of management for DTC, even in the presence of metastasis, to facilitate adjuvant therapies. * **Option C:** While it includes surgery and radiotherapy, it misses **Radioiodine**, which is the most specific systemic therapy for thyroid cancer cells. **NEET-PG High-Yield Pearls:** * **Most common site of metastasis in PTC:** Cervical lymph nodes (Level II, III, IV). * **Most common site of distant metastasis:** Lungs (more common than bone). * **Prognostic Scoring:** Use the **AMES** or **MACIS** criteria for PTC. * **Thyroglobulin (Tg):** Used as a postoperative tumor marker to monitor recurrence. * **Treatment of choice for Follicular Carcinoma with bone metastasis:** Also Total Thyroidectomy followed by RAI.

Question 4: A 3 cm squamous cell carcinoma of the retrornolar trigone is invading the mandible and the medial pterygoid muscle. What is the TNM stage of this tumor?

A. Stage I
B. Stage II
C. Stage III
D. Stage IV (Correct Answer)

Explanation: ### Explanation The TNM staging for Oral Cavity cancers (including the retromolar trigone) is based on the size and depth of invasion (T), nodal involvement (N), and metastasis (M). **1. Why Stage IV is Correct:** According to the AJCC 8th Edition, the T-stage is determined by the extent of local invasion. * **T4a (Moderately Advanced Local Disease):** The tumor invades adjacent structures such as the cortical bone of the mandible or maxilla, deep (extrinsic) muscles of the tongue, maxillary sinus, or skin of the face. * **T4b (Very Advanced Local Disease):** The tumor invades the masticator space (which includes the **medial pterygoid muscle**), pterygoid plates, or skull base, and/or encases the internal carotid artery. In this case, invasion into the **medial pterygoid muscle** automatically classifies the tumor as **T4b**. Any T4 tumor (T4a or T4b) with any N or M status results in a **Stage IV** designation (specifically Stage IVB for T4b). **2. Why Other Options are Incorrect:** * **Stage I:** Requires a T1 tumor (≤2 cm and Depth of Invasion [DOI] ≤5 mm) with no nodal involvement. * **Stage II:** Requires a T2 tumor (>2 cm and ≤4 cm, DOI ≤10 mm) with no nodal involvement. * **Stage III:** Requires a T3 tumor (>4 cm or DOI >10 mm) or a T1/T2/T3 tumor with a single ipsilateral lymph node ≤3 cm (N1). **3. Clinical Pearls for NEET-PG:** * **Retromolar Trigone (RMT):** A unique site where the mucosa is closely attached to the bone; hence, early bone invasion is common. * **Masticator Space:** Involvement of the medial pterygoid often presents clinically as **trismus** (lockjaw), which is a "red flag" for T4b disease. * **Bone Invasion:** Superficial erosion of bone/tooth socket by a gingival primary is not enough to classify as T4; there must be invasion through the cortical bone.

Question 5: A 42-year-old man is undergoing chemotherapy after resection of a cecal adenocarcinoma with positive lymph nodes. Which of the following potentially operable complications is a common occurrence among patients receiving systemic chemotherapy?

A. Acute cholecystitis
B. Perirectal abscess (Correct Answer)
C. Appendicitis
D. Diverticulitis

Explanation: **Explanation:** The correct answer is **Perirectal abscess**. **1. Why Perirectal Abscess is Correct:** Patients undergoing systemic chemotherapy for malignancies (like cecal adenocarcinoma) frequently experience **neutropenia**. In a neutropenic state, the mucosal integrity of the gastrointestinal tract is often compromised (mucositis). The perianal and perirectal areas are highly colonized with bacteria; minor trauma or cryptoglandular infection in an immunocompromised host can rapidly progress to a perirectal abscess or necrotizing soft tissue infection. Notably, in neutropenic patients, classic signs of inflammation (redness, fluctuance, or pus) may be absent, making **exquisite localized pain** the most reliable clinical indicator. **2. Why the Other Options are Incorrect:** * **Acute Cholecystitis:** While it can occur in hospitalized patients (especially acalculous cholecystitis in the ICU), it is not a specific or "common" complication directly attributed to the systemic effects of standard chemotherapy compared to perirectal infections. * **Appendicitis:** The incidence of appendicitis in patients on chemotherapy is not significantly higher than in the general population. Furthermore, in this specific patient, the **cecum has already been resected**, meaning the appendix was likely removed during the primary surgery. * **Diverticulitis:** While chemotherapy (specifically VEGF inhibitors like Bevacizumab) can increase the risk of bowel perforation, primary diverticulitis is not a standard "common occurrence" triggered by neutropenia in the same way perirectal infections are. **3. NEET-PG High-Yield Pearls:** * **Neutropenic Enterocolitis (Typhlitis):** Another critical surgical complication of chemotherapy, typically involving the cecum. It presents with RLQ pain, fever, and neutropenia. * **Clinical Sign:** In a neutropenic patient with a perirectal abscess, **digital rectal examination (DRE)** should be performed with extreme caution or avoided to prevent bacteremia, unless necessary for diagnosis. * **Management:** Prompt broad-spectrum antibiotics are the mainstay; surgical drainage is indicated if there is evidence of fluctuance or if the infection does not respond to medical therapy.

Question 6: The Astler-Coller modification of the Dukes classification is used to classify cancers of which organ?

A. Liver
B. Colon (Correct Answer)
C. Lung
D. Stomach

Explanation: **Explanation:** The **Astler-Coller modification** is a clinical and pathological staging system specifically designed for **Colorectal Carcinoma**. It is an evolution of the original Dukes classification, refined to better reflect the prognostic significance of the depth of tumor invasion and the presence of lymph node involvement. **Why Colon is Correct:** The system categorizes colorectal cancer based on the extent of local spread: * **A:** Limited to mucosa. * **B1:** Extending into muscularis propria but not through it (nodes negative). * **B2:** Penetrating through muscularis propria (nodes negative). * **C1:** Extending into muscularis propria (nodes positive). * **C2:** Penetrating through muscularis propria (nodes positive). * **D:** Distant metastasis. This refinement is crucial because, in the Astler-Coller system, the "C" stage is subdivided to show that transmural extension (C2) carries a worse prognosis than intramural spread (C1) even when nodes are positive. **Why Other Options are Incorrect:** * **Liver:** Primary liver cancers (HCC) are typically staged using the **BCLC (Barcelona Clinic Liver Cancer)** system or the TNM system. * **Lung:** Lung cancer uses the **TNM staging** system (AJCC), which focuses heavily on tumor size, hilar/mediastinal node involvement, and distant spread. * **Stomach:** Gastric cancer is staged using the **Japanese Gastric Cancer Association (JGCA)** classification or the standard TNM system. **High-Yield Clinical Pearls for NEET-PG:** * **Dukes Classification (Original):** A (Submucosa), B (Muscularis), C (Nodes). * **Astler-Coller Key:** It specifically introduced the distinction between **B1/B2** and **C1/C2** based on the penetration of the *muscularis propria*. * **Current Gold Standard:** While Astler-Coller is historically significant and frequently tested, the **AJCC TNM system** is the current clinical standard for colorectal cancer staging. * **Prognostic Factor:** The most important prognostic factor in colorectal cancer is the **number of lymph nodes involved**.

Question 7: What is the role of neoadjuvant chemotherapy in breast carcinoma patients?

A. Curing distant metastasis
B. To shrink the tumor to enable breast-conserving therapy (Correct Answer)
C. Limiting metastasis
D. Symptomatic relief

Explanation: ### Explanation **Neoadjuvant Chemotherapy (NACT)** refers to the administration of systemic chemotherapy before definitive local surgical treatment. **1. Why Option B is Correct:** The primary surgical objective of NACT in breast cancer is **downstaging**. By shrinking a large primary tumor, NACT can convert a patient who was initially a candidate only for a Total Mastectomy into a candidate for **Breast Conserving Surgery (BCS)**. It also helps in downstaging involved axillary lymph nodes, potentially avoiding a morbid axillary lymph node dissection (ALND). **2. Why Other Options are Incorrect:** * **Option A & C:** While NACT treats micrometastases early, it is not a "cure" for established distant metastasis (Stage IV), nor is its primary definition "limiting" metastasis; its role is local downstaging for better surgical outcomes. * **Option D:** Symptomatic relief is the goal of *palliative* chemotherapy. NACT is part of a *curative* intent protocol. **3. NEET-PG High-Yield Pearls:** * **Indications for NACT:** Locally Advanced Breast Cancer (LABC), inflammatory breast cancer, or large tumors where the tumor-to-breast ratio precludes BCS. * **Pathological Complete Response (pCR):** The most important prognostic marker after NACT. It is defined as the absence of invasive cancer in the breast and axilla at the time of surgery. * **Molecular Subtypes:** Triple-negative (TNBC) and HER2-positive breast cancers show the highest rates of pCR with NACT. * **Monitoring:** The clinical response to NACT is monitored via physical exam and imaging (MRI is the most sensitive). If the tumor progresses during NACT, surgery should be performed immediately.

Question 8: What is the most common site for cancer of the tongue?

A. Base of tongue
B. Tip of tongue
C. Lateral margin of tongue (Correct Answer)
D. Posterior attachment of tongue

Explanation: **Explanation:** The **lateral margin of the tongue** (specifically the middle third) is the most common site for squamous cell carcinoma (SCC) of the tongue, accounting for approximately **75% of cases**. This area is particularly vulnerable due to chronic irritation from jagged teeth or ill-fitting dentures, and the pooling of carcinogens (like alcohol and tobacco) in the floor of the mouth and the adjacent lateral sulcus. **Analysis of Options:** * **A. Base of tongue:** This refers to the posterior one-third (behind the circumvallate papillae). While it is a common site for HPV-associated oropharyngeal cancers, it is less frequent than lateral margin involvement. * **B. Tip of tongue:** This is a rare site for primary malignancy. * **D. Posterior attachment:** This is not a standard anatomical landmark for primary tongue cancer localization; most cancers arise on the mobile (anterior two-thirds) portion. **Clinical Pearls for NEET-PG:** 1. **Histology:** Squamous Cell Carcinoma (SCC) is the most common histological type (>90%). 2. **Lymphatic Spread:** Tongue cancers have a high propensity for early lymphatic spread. The tip drains to Submental nodes (Level I), while the lateral margins drain to Submandibular (Level I) and Deep Cervical nodes (Level II/III). 3. **Premalignant Lesions:** Erythroplakia has a much higher risk of malignant transformation than Leukoplakia. 4. **Prognosis:** Tumors of the posterior third (base) generally have a worse prognosis than the anterior two-thirds because they are often diagnosed late and have a higher rate of bilateral nodal metastasis.

Question 9: A 40-year-old man presents with pulmonary lesions on chest CT scan. He has a history of melanoma treated with wide local excision and lymph node dissection. Biopsy confirms metastatic melanoma in the pulmonary lesions. His general condition is good, with no evidence of recurrence or extrathoracic disease. What is the most appropriate treatment for this patient?

A. Pulmonary metastasectomy followed by radiation therapy
B. Pulmonary metastasectomy (Correct Answer)
C. Chemotherapy
D. Radiation therapy

Explanation: **Explanation:** The correct answer is **Pulmonary Metastasectomy**. In surgical oncology, the management of metastatic disease is governed by specific criteria. For pulmonary metastases, surgical resection is indicated when the primary tumor is controlled, there is no extrathoracic disease, the patient is medically fit for surgery, and a complete (R0) resection is technically feasible. **Why Pulmonary Metastasectomy is correct:** In this patient, the primary melanoma has been treated, there is no evidence of recurrence elsewhere, and his general condition is good. For isolated pulmonary metastases from solid tumors (like melanoma, osteosarcoma, or colorectal cancer), metastasectomy offers the best chance for long-term survival and, in some cases, a potential cure. **Why other options are incorrect:** * **A. Followed by radiation therapy:** Post-operative radiation is not standard for pulmonary metastases unless there is positive margin (R1/R2) or specific palliative needs. * **C. Chemotherapy:** While systemic therapy (immunotherapy/targeted therapy) is common in Stage IV melanoma, surgery remains the preferred local treatment for resectable, isolated lung nodules in a fit patient to achieve a "disease-free" state. * **D. Radiation therapy:** Radiation is generally reserved for palliation or for patients who are not surgical candidates (Stereotactic Body Radiotherapy - SBRT). **Clinical Pearls for NEET-PG:** * **Thomford’s Criteria:** The classic criteria for metastasectomy include: (1) Primary site controlled, (2) No extrapulmonary disease, (3) Resectable lesions, (4) Adequate pulmonary reserve. * **Most common source of lung metastasis:** Breast, GI tract, and Kidneys. * **Best Prognosis:** Metastasectomy for **Osteosarcoma** and **Testicular tumors** often yields the highest survival rates. * **Melanoma specific:** While historically resistant to chemo, isolated surgical resection of melanoma metastases can significantly improve 5-year survival compared to systemic therapy alone.

Question 10: What is the use of injecting methylene blue dye in breast cancer surgery?

A. Tattooing for biopsy
B. Marking of tumor cells
C. Sentinel lymph node biopsy (Correct Answer)
D. Photodynamic therapy

Explanation: **Explanation:** **Sentinel Lymph Node Biopsy (SLNB)** is the standard of care for axillary staging in clinically node-negative (cN0) breast cancer. The "Sentinel Node" is defined as the first lymph node(s) to receive lymphatic drainage from the primary tumor. Injecting **Methylene Blue** (or Isosulfan Blue/Patent Blue) into the periareolar area or the peritumoral tissue allows the surgeon to visually track the blue-stained lymphatic channels leading to the blue-stained sentinel node. This allows for targeted removal of only the most relevant nodes, reducing the risk of lymphedema compared to a full axillary dissection. **Analysis of Incorrect Options:** * **A. Tattooing for biopsy:** While dyes or charcoal can be used to mark non-palpable lesions for excision, Methylene Blue is not used for permanent tattooing as it diffuses rapidly. * **B. Marking of tumor cells:** Methylene Blue does not selectively bind to or "stain" breast cancer cells; it follows lymphatic flow. * **D. Photodynamic therapy:** This involves photosensitizers (like porphyrins) and specific light wavelengths to kill cancer cells, not diagnostic blue dyes. **High-Yield Clinical Pearls for NEET-PG:** * **Dual Technique:** The highest identification rate for SLNB is achieved using a combination of **Methylene Blue dye** and **Radioactive Technetium-99m sulfur colloid** (detected via a Gamma probe). * **Contraindication:** SLNB is generally avoided in inflammatory breast cancer. * **Side Effect:** Patients should be warned that Methylene Blue can cause temporary blue-green discoloration of urine and skin. * **Safety Note:** Isosulfan blue carries a small risk of anaphylaxis; Methylene Blue is a safer, cost-effective alternative.

Practice by Chapter

Principles of Surgical Oncology

Practice Questions

Cancer Staging

Practice Questions

Surgical Margins in Cancer Surgery

Practice Questions

Sentinel Lymph Node Concepts

Practice Questions

Neoadjuvant and Adjuvant Therapy

Practice Questions

Metastasectomy

Practice Questions

Cytoreductive Surgery

Practice Questions

Hyperthermic Intraperitoneal Chemotherapy

Practice Questions

Palliative Surgical Procedures

Practice Questions

Minimally Invasive Approaches in Cancer Surgery

Practice Questions

Follow-up and Surveillance

Practice Questions

Hereditary Cancer Syndromes

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free